Market News & Trends
Synteract Expands Into Asia Pacific & South Africa Through Acquisition of Specialty Biometrics CRO
Synteract recently acquired Clindata’s human health biometrics division to meet market demand for more adaptable biometrics services solutions. This acquisition extends Synteract’s existing global footprint…
CURE Pharmaceutical Signs Exclusive Licensing Agreement With ReLeaf Europe
CURE Pharmaceutical recently announced it has signed an exclusive licensing agreement with ReLeaf Europe, one of Europe’s leading pharmaceutical groups specialized in medicinal cannabis products.…
AskBio Announces First Patient Dosed in Phase 1 Trial
Asklepios BioPharmaceutical (AskBio) and its NanoCor Therapeutics subsidiary recently announced that the first patient has been dosed in a Phase 1 clinical trial of NAN-101.…
Cellectricon & StressMarq Biosciences Collaborate to Develop Next-Generation Reagents & Assays
Cellectricon recently announced a collaboration with StressMarq Biosciences. As a supplier of life science reagents such as primary antibodies, antibody conjugates, proteins, immunoassay kits and…
PharmaCyte Biotech Will Have All the Protection It Needs Upon Marketing Approval
PharmaCyte Biotech recently announced it is about to embark upon a planned US FDA Phase 2b clinical trial to treat locally advanced, inoperable pancreatic cancer (LAPC) at trial sites all over the US, and with that journey comes the….
Two Labs Acquires CEEK Enterprises
Two Labs recently announced it has acquired CEEK Enterprises, a management consultancy dedicated to supporting clients in the biopharma and MedTech industries with specialized expertise in….
Pelican BioThermal Announces the Acquisition of NanoCool
Pelican BioThermal recently announced the acquisition of NanoCool, an Albuquerque, New Mexico-based manufacturer of temperature-controlled packaging solutions. This acquisition further…..
Catalent to Acquire Leading Cell Therapy Company MaSTherCell Global
Catalent, Inc. recently announced it has agreed to acquire MaSTherCell Global, a company backed by Great Point Partners, SFPI-FPIM, and Orgenesis Inc. for an aggregate of…..
Conatus Pharmaceuticals & Histogen Enter Definitive Merger Agreement
Conatus Pharmaceuticals Inc. and Histogen Inc. recently announced the companies have entered into a definitive agreement under which Histogen will merge with a wholly owned subsidiary of….
Albireo Achieves Significant Milestones for Odevixibat Across Multiple Diseases
Albireo Pharma, Inc. recently announced a number of advances and new initiatives in the clinical program for odevixibat, an oral once daily capsule in development for….
BioPharmX & Timber Pharmaceuticals Announce Merger Agreement
BioPharmX Corporation and Timber Pharmaceuticals LLC recently announced they have entered into a definitive merger agreement. Under the terms of the merger agreement, subject to the approval of…..
Ubiquigent Launches a New Service to Facilitate Target Validation of DUB Enzymes & Determine Compound-DUB Target Engagement & Selectivity of Novel Compounds in Cells
Ubiquigent Limited (Ubiquigent) recently announced the launch of an exciting new service as part of its Drug Discovery Screening Platform – DUBprofiler-Cell. DUBprofiler-Cell supports the…
Rubius Therapeutics Announces First Patient Dosed in Phase 1b Trial of RTX-134
Rubius Therapeutics, Inc. recently announced that the first patient has been dosed in its Phase 1b trial of RTX-134, an allogeneic, off-the-shelf cellular therapy for…
Vetter Aligns its Development Service Laboratory Portfolio
Vetter, a global operating Contract Development and Manufacturing Organization (CDMO) has brought together its development laboratories in one Ravensburg site end of last year. Designed…
Avacta’s Proprietary TMAC Cancer Therapy Platform Demonstrates Successful Proof-of-Concept
Avacta Group plc recently announced it has demonstrated initial proof-of-concept for its proprietary new class of drug conjugate, TMAC, in a preclinical animal model of…
Cabaletta Bio Receives Orphan Drug Designation for DSG3-CAART
Cabaletta Bio, Inc. recently announced that the US FDA has granted Orphan Drug Designation for the company’s lead product candidate, DSG3-CAART, for the treatment of…
Akcea & Ionis Report Positive Topline Phase 2 Study Results
Akcea Therapeutics, Inc. and Ionis Pharmaceuticals, Inc. recently announced positive topline results from the Phase 2 study of AKCEA-ANGPTL3-LRx in patients with hypertriglyceridemia, type 2…
Hovione Technology Announces Key Patent Grants for its Large-Dose DPI
Hovione Technology recently announced the notice of patent grants in key territories of the world for one of its Large-Dose dry powder inhaler (DPI) platforms,…
Drug Developers Are Making Strides in Streamlining Patient Recruitment & Retention for Clinical Trials
Efforts by drug developers during the past decade to improve recruitment and retention of patients for clinical trials appear to be paying off, as enrollment…
Theralase Granted US Patent for Multiwavelength Photodynamic Therapy
Theralase Technologies Inc. recently announced it has been granted a US Patent for Multiwavelength PhotoDynamic Therapy (PDT) technology. The US patent, titled Apparatus and Method…
